Alpha Tau to Present at the Jefferies Global Healthcare Conference
May 21, 2024 08:45 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 20, 2024 16:01 ET
|
Alpha Tau Medical Ltd.
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow - - First patient with liver metastases treated in a...
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
May 13, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
May 06, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone - Effect seen across both...
Alpha Tau to Participate in May Investor Conferences
May 01, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
March 25, 2024 08:50 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024 16:01 ET
|
Alpha Tau Medical Ltd.
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently...
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
February 26, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023 09:15 ET
|
Alpha Tau Medical Ltd.
- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well...
Alpha Tau to Participate in Sidoti Small-Cap Conference
November 29, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...